LEFTY1, a secreted dual inhibitor of the NODAL/SMAD2 and
BMP7/SMAD5 pathway, is implicated in driving cancer stem cell
biology and unregulated tumor cell growth
Tachyon Therapeutics, Inc. (Tachyon), a research and development
focused biotechnology company, and AbCellera (Nasdaq: ABCL), a
technology company with a centralized operating system for
next-generation antibody discovery, today announced a collaboration
to facilitate the discovery and development of a therapeutic
antibody targeting LEFTY1, a member of the transforming growth
factor β (TGF-β) superfamily and validated extracellular drug
target expressed in advanced cancers. Under the terms of the
agreement, AbCellera is eligible to receive milestone payments and
royalties on products that are derived from its antibody discovery
platform. In addition, AbCellera has the option to invest in
preclinical and clinical development in exchange for an increased
share of product sales.
“At Tachyon, we are focused on innovation, precision, science,
and speed to develop first-in-class therapeutics against
significant new drug targets in cancer biology,” said Frank Perabo,
M.D., Ph.D., Chief Executive Officer of Tachyon. “AbCellera has
consistently demonstrated these four qualities as they accelerate
the discovery of first-in-class therapeutic antibodies for novel
biology. We look forward to working with their team to target
LEFTY1, a major signaling regulator of the TGF-β superfamily, and
unlock a new pathway to treat advanced cancers.”
Members of the TGF-β superfamily control numerous cellular
functions, including proliferation, apoptosis, differentiation,
epithelial-mesenchymal transition, adhesion, and migration. Because
of their ubiquitous and regulatory roles in both normal and cancer
cell biology, TGF-β superfamily members, such as LEFTY1 are highly
sought after, yet challenging drug targets. Research led by
Tachyon’s scientific founder, Michael F. Clarke, Ph.D., who was the
first to identify and characterize cancer stem cells in solid
tumors, revealed that LEFTY1 suppresses NODAL/SMAD2 and BMP7/SMAD5
pathways to promote long-term proliferation of normal and malignant
mammary epithelial cells.1 As a secreted extracellular protein,
LEFTY1 represents an important target to control SMAD-dependent
signals that promote the long-term growth and self-renewal of
cancer stem cells.
“Our collaboration with Tachyon represents an opportunity to
expedite the translation of breakthrough research of a novel and
significant cancer drug target into a first-in-class antibody
therapeutic for patients with advanced cancers and limited
treatment options,” said Carl Hansen, Ph.D., CEO of AbCellera.
“This collaboration exemplifies innovative deal structures that
align our interest with our partners’ and provides AbCellera with
optionality to deepen our participation in the success of the
antibodies we discover. We are excited to partner with Tachyon to
pursue a previously unexplored mechanism and develop therapies that
we anticipate will impact cancer treatment.”
1. Zabala, et al., LEFTY1 Is a Dual-SMAD Inhibitor that Promotes
Mammary Progenitor Growth and Tumorigenesis. Cell Stem Cell.
2020.
About Tachyon Therapeutics Inc.
Tachyon Therapeutics, Inc. is a R&D focused biotechnology
company developing novel, first-in-class therapeutics for the
treatment of advanced cancers. Tachyon operates with a dedicated
internal core development team and a virtual external network of
expertise to achieve one goal – advance development of promising
drug targets with speed and innovation, without compromising the
quality or integrity of science. For more information, please visit
www.tachyontx.com.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210803005352/en/
Tachyon Inquiries Frank Perabo, M.D., Ph.D., Chief
Executive Officer; ir@tachyontx.com, +1 (832) 952-0829
AbCellera Inquiries Media: Jessica Yingling, Ph.D.,
media@abcellera.com, +1 (236) 521-6774 Business Development: Neil
Berkley, bd@abcellera.com, +1 (604) 559-9005 Investor Relations:
Melanie Solomon, ir@abcellera.com, +1 (778) 729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024